Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | BACE1 | P56817 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PPIA | P62937 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | CIT | O14578 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400060 | 1.00 | MMP2 (0.62) | MMP2MEN1KMT2ABACE1MAPT | |
| Hydrochloric Acid SCHEMBL5966808 | 0.99 | MMP2 (0.61) | MMP2MEN1KMT2ABACE1MAPT | |
| Ammonia Solution, Strong SCHEMBL27392946 | 0.99 | MMP2 (0.61) | MMP2MEN1KMT2ABACE1MAPT | |
| SCHEMBL6407141 | 0.92 | MMP2 (0.55) | MMP2MEN1KMT2ABACE1MAPT | |
| SCHEMBL5668485 | 0.91 | MMP2 (0.53) | MMP2MEN1KMT2ABACE1MAPT | |
| SCHEMBL1172502 | 0.89 | MMP2 (0.54) | MMP2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL23466426 | 0.88 | MEN1 (0.60) | MMP2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL23466428 | 0.88 | MEN1 (0.60) | MMP2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL29402169 | 0.88 | MMP2 (0.63) | MMP2MEN1KMT2ABACE1LMNA | |
| SCHEMBL28183373 | 0.87 | MMP2 (0.55) | MMP2MEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092336-A1 | PROTEASE VARIANTS AND USES THEREOF | DANISCO US INC (US) | 2025-03-20 | — | — | US | claimed |
| US-12146122-B2 | Protease variants and uses thereof | DANISCO US INC. (US) | 2024-11-19 | — | — | US | claimed |
| US-20240093124-A1 | PROTEASE VARIANTS AND USES THEREOF | DANISCO US INC (US) | 2024-03-21 | — | — | US | claimed |
| US-11661567-B2 | Protease variants and uses thereof | DANISCO US INC. (US) | 2023-05-30 | — | — | US | claimed |
| US-11499146-B2 | Bacillus gibsonii-clade serine proteases | DANISCO US INC. (US) | 2022-11-15 | — | — | US | claimed |
| US-20070059758-A1 | Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding | THE GOVERNMENT OF THE USA OF AMERICA, REP. BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-03-15 | — | — | US | claimed |
| US-20030215820-A1 | Interleukins; aminopeptidases; blot analysis; drug screening | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-11-20 | — | — | US | claimed |
| US-6303360-B1 | CULTURING SPHINGOMONAS; MOLECULAR HYBRIDIZATION; GENETIC ENGINEERING; HYDROLYZES ANILIDES OF ALANINE, GLYCINE, LEUCINE, GLUTAMIC ACID, ASPARTIC ACID, LYSINE, ISOLEUCINE, AND VALINE | NOVOZYMES BIOTECH, INC, | 2001-10-16 | — | — | US | claimed |
| WO-2001064856-A2 | REGULATORS OF TYPE-1 TUMOR NECROSIS FACTOR RECEPTOR AND OTHER CYTOKINE RECEPTOR SHEDDING | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, A S REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEA LTH AND HUMAN SERVICES (US) | 2001-09-07 | — | — | WO | claimed |
| US-6184020-B1 | AMINO ACID AND NUCLEOTIDE SEQUENCE; FOR PRODUCTION OF PROTEIN HYDROLYSATES USED AS FLAVORINGS IN FOODS | NOVO NORDISK BIOTECH, INC. | 2001-02-06 | — | — | US | claimed |
| US-5480779-A | ADDING TO SAMPLE PREDETERMINED AMOUNT OF ISOMERASE ISOMERIZING PEPTIDE N-TERMINAL TO PROLINE, MEASURING ENZYME-CATALYZED ISOMERIZATION OF PROLINE-CONTAINING PEPTIDE SUBSTRATE, DETERMINING CYCLOSPORIN CONCENTRATION FROM CALIBRATION CURVE | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 1996-01-02 | — | — | US | claimed |
| EP-0360029-B1 | METHOD AND ASSAY TO DETERMINE THE CONCENTRATION OF CYCLOSPORINS | ARZNEIMITTELWERK DRESDEN GmbH (DE) | 1993-08-04 | — | — | EP | claimed |
| JP-2150298-A | — | — | None | — | — | JP | disclosed |
| US-20260146243-A1 | COMPOSITIONS AND METHODS COMPRISING VARIANT MICROBIAL PROTEASES | DANISCO US INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4745232-A2 | PROTEASE VARIANTS WITH IMPROVED PERFORMANCE | Henkel AG & Co. KGaA (DE) | 2026-05-20 | — | — | EP | disclosed |
| US-12630812-B2 | Subtilase variants and polynucleotides encoding same | NOVOZYMES A/S (DK) | 2026-05-19 | — | — | US | disclosed |
| WO-1991013904-A1 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | CEPHALON, INC. (US) | 1991-09-19 | — | — | WO | disclosed |
| EP-0379342-A2 | New FK-506 cytosolic binding protein | MERCK & CO. INC. (US) | 1990-07-25 | — | — | EP | disclosed |
| JP-H02150298-A | METHOD AND ASSAY FOR DETERMINATION OF CONCENTRATION OF CYCLOSPORINE | VEB ARZNEIMITTEL WERK DRESDEN | 1990-06-08 | — | — | JP | disclosed |
| WO-1986007281-A1 | METHOD FOR THE PURIFICATION OF BIOACTIVE SUBSTANCES BY BIOSPECIFIC ADSORPTION | BATTELLE MEMORIAL INSTITUTE (CH) | 1986-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146243-A1 | COMPOSITIONS AND METHODS COMPRISING VARIANT MICROBIAL PROTEASES | HPN, CTRL, PRSS1 | MMP2 56/4885MEN1 588/4885KMT2A 3854/4885 |
| US-12630812-B2 | Subtilase variants and polynucleotides encoding same | RNASE1, PEPD, DPP9 | MMP2 107/4885MEN1 3634/4885KMT2A 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.